6/18/2020 8:39:21 AM
NuVasive Launches Reline 3D, Posterior Fixation System For Patients Suffering From Pediatric Spinal Deformities
5/28/2020 12:20:12 AM
NuVasive Announces Pricing Of Offering Of $400 Mln Of 1.00% Convertible Senior Notes Due 2023
5/26/2020 4:09:55 PM
NuVasive Announces Proposed Offering Of $400 Million Of Convertible Senior Notes Due 2023
5/6/2020 4:04:42 PM
NuVasive Q1 GAAP EPS $0.10; Non-GAAP EPS $0.48
5/5/2020 8:34:46 AM
NuVasive Expands Advanced Materials Science Implant Portfolio To Additional Thoracolumbar Procedures
3/10/2020 8:37:46 AM
NUVA: Attrax Putty Ceramic Bone Graft Substitute Supported By Level I Evidence To Show Non-inferior Fusion Performance
2/27/2020 2:26:02 AM
NuVasive Reports Pricing Of Offering Of $450 Mln Of 0.375% Convertible Senior Notes Due 2025
2/26/2020 8:06:47 AM
NuVasive Announces Proposed Offering Of $450 Mln Of Convertible Senior Notes Due 2025
2/20/2020 4:04:07 PM
NuVasive Q4 GAAP EPS $0.55; Non-GAAP EPS $0.73
1/13/2020 8:35:31 AM
NuVasive Q4 Revenue Of About $310 Mln, Increased About 8% On Both Reported And Constant Currency Basis
1/2/2020 4:06:34 PM
NuVasive Appoints Matthew Harbaugh As CFO
11/21/2019 8:34:20 AM
NuVasive Receives FDA 510(k) Clearance For Expanded Indications For The CoRoent Small Interlock System